{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:33:04Z","timestamp":1786361584237,"version":"build-2736575974"},"reference-count":5,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>Traumatic brain injury (TBI) continues to be a major global cause of morbidity and mortality, with neuroinflammation recognized as a central mechanism influencing both acute and long-term outcomes. Following the initial insult, activation of glial cells, cytokine release, and blood\u2013brain barrier disruption drive a cascade of secondary injury. While these inflammatory processes contribute to debris clearance and neurorepair, excessive or prolonged activation leads to neuronal death and chronic neurodegeneration. Recent international research has focused on modulating these pathways to enhance recovery. In the United States and Germany, trials using stem cell derived exosomes and anti-cytokine biologics have shown neuroprotective potential. In China, novel compounds such as 3-monothiopomalidomide have demonstrated efficacy in reducing microglial activation and improving behavioral outcomes in experimental TBI. Integrating these pharmacological, cellular, and imaging innovations into clinical care could transform TBI management. This letter underscores the need for global collaboration, transparent data use, and biomarker-driven neuroinflammatory modulation to optimize adult brain injury recovery.<\/jats:p>","DOI":"10.1097\/ms9.0000000000004642","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T15:01:59Z","timestamp":1767711719000},"page":"2156-2157","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Targeting neuroinflammation to enhance recovery after brain injury"],"prefix":"10.1097","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5229-5052","authenticated-orcid":false,"given":"Muhammad","family":"Khizar","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Georgian American University, Manifest Medical Research Co., Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7675-7161","authenticated-orcid":false,"given":"Muhammad","family":"Zaib","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Georgian American University, Manifest Medical Research Co., Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4741-7631","authenticated-orcid":false,"given":"Meerab","family":"Babar","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9243-7960","authenticated-orcid":false,"given":"Mahnoor","family":"Fatima","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Shaheed Ziaur Rahman Medical College, Rajshahi Medical University, Bogura, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"R1-20260810","doi-asserted-by":"crossref","first-page":"137\u201351","DOI":"10.1016\/j.cjtee.2018.02.003","article-title":"Current understanding of neuroinflammation after traumatic brain injury and cell-based therapeutic opportunities","volume":"21","author":"Xiong","year":"2018","journal-title":"Chin J Traumatol"},{"key":"R2-20260810","doi-asserted-by":"crossref","first-page":"855701","DOI":"10.3389\/fimmu.2022.855701","article-title":"Neuroinflammation following traumatic brain injury: take it seriously or not","volume":"13","author":"Zheng","year":"2022","journal-title":"Front Immunol"},{"key":"R3-20260810","first-page":"88","article-title":"Translational advances in anti-inflammatory therapies after brain injury","volume":"21","author":"Xiong","year":"2024","journal-title":"J Neuroinflamm"},{"key":"R4-20260810","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12929-025-01150-w","article-title":"Targeting neuroinflammation: 3-monothiopomalidomide a new drug candidate to mitigate traumatic brain injury and neurodegeneration","volume":"32","author":"Hsueh","year":"2025","journal-title":"J Biomed Sci"},{"key":"R5-20260810","doi-asserted-by":"crossref","DOI":"10.70389\/PJS.100082","article-title":"Transparency in the reporting of Artificial Intelligence \u2013 the TITAN guideline","author":"Agha","year":"2025","journal-title":"Prem Sci"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000004642","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:04:08Z","timestamp":1786359848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000004642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000004642","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"2025-10-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}